Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer

Exclusion Criteria

• •Patients who are pregnant or lactating
• •Radiation, chemotherapy, or immunotherapy or any other anticancer therapy =\< 3 weeks prior to cycle 1 day 1; mitomycin C or radio-immunotherapy 6 weeks prior to cycle 1 day 1
• •Major surgery within four weeks before cycle 1 day 1
• •Unstable cardiovascular function:
• •* Symptomatic ischemia, or
• •* Uncontrolled clinically significant conduction abnormalities (e.g.: ventricular tachycardia on antiarrhythmics are excluded and 1st degree atrioventricular \[AV\] block or asymptomatic left anterior fascicular block \[LAFB\]/right bundle branch block \[RBBB\] will not be excluded), or
• •* Congestive heart failure (CHF) of New York Heart Association (NYHA) class \>= 3, or
• •* Myocardial infarction (MI) within 3 months of cycle 1 day 1 dose
• •Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose
• •Known to be HIV seropositive who are on anti-HIV drugs because of the unknown interactions between these drugs and the study agents
• •Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C virus (HCV) ribonucleic acid (RNA) or HBsAg (hepatitis B virus \[HBV\] surface antigen)
• •Patients with active central nervous system (CNS) malignancy; asymptomatic small lesions are not considered active; treated lesions may be considered inactive if they are stable for at least 3 months
• •Patients with significantly diseased or obstructed gastrointestinal tract or uncontrolled vomiting or diarrhea
• •Grade \>= 2 peripheral neuropathy within 14 days prior to cycle 1 day 1
• •History of seizures, movement disorders or cerebrovascular accident within the past 5 years prior to cycle 1 day 1
• •Patients with muscular degeneration, uncontrolled glaucoma, or markedly decreased visual acuity based on physician's assessment
• •Serious psychiatric or medical conditions that could interfere with treatment
• •Participation in an investigational anti-cancer study within 3 weeks prior to cycle 1 day 1
• •Concurrent therapy with approved or investigational anticancer therapeutic
• •Presence of clinically significant ascites